Viracta Therapeutics, Inc.
VIRX · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | 83.3% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -1,719.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -1,865.2% |
| EPS Diluted | -0.27 | -0.25 | -0.23 | -0.35 |
| % Growth | -8% | -8.7% | 34.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |